Alphamab Oncology (STU:3NK) Beginning Cash Position: €100.10 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3NK Alphamab Oncology STU:3NK
55 GF Score
Price €0.89
GF Value €0.83
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Beginning Cash Position?

Alphamab Oncology STU:3NK +2.89% 55 Beginning Cash Position is €100.10 Mil as of Dec. 2025. GuruFocus rates STU:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.83. The stock has 4 warning signs investors should review.

Alphamab Oncology's Beginning Cash Position for the quarter that ended in Dec. 2025 was €100.10 Mil.

Alphamab Oncology's quarterly Beginning Cash Position declined from Dec. 2024 (€149.56 Mil) to Jun. 2025 (€134.28 Mil) and declined from Jun. 2025 (€134.28 Mil) to Dec. 2025 (€100.10 Mil).

Alphamab Oncology's annual Beginning Cash Position increased from Dec. 2023 (€137.31 Mil) to Dec. 2024 (€142.45 Mil) but then declined from Dec. 2024 (€142.45 Mil) to Dec. 2025 (€134.85 Mil).

Alphamab Oncology Beginning Cash Position Related Terms

Alphamab Oncology Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Beginning Cash Position Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 25.75 108.77 137.31 142.45 134.85

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.93 139.07 149.56 134.28 100.10
STU:3NK
55GF Score
Alphamab Oncology STU:3NK
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €100.10 Mil mean?
Alphamab Oncology (STU:3NK) has a Beginning Cash Position of €100.10 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Beginning Cash Position too high?
Alphamab Oncology's current Beginning Cash Position is €100.10 Mil. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Beginning Cash Position compare to VRTX and REGN?
Alphamab Oncology's Beginning Cash Position of €100.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Beginning Cash Position is €100.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (STU:3NK) has a current Beginning Cash Position of €100.10 Mil. The stock's GF Value™ is €0.83, compared to a current price of €0.89 — trading 7.2% above its estimated fair value. The current Beginning Cash Position is €100.10 Mil. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Alphamab Oncology (STU:3NK), the current Beginning Cash Position is €100.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (STU:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.89 is trading 7.2% above its estimated GF Value™ of €0.83.

Key valuation signals for STU:3NK:

  • Beginning Cash Position: €100.10 Mil
  • GF Value™: €0.83 vs. price of €0.89 (7.2% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the STU:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for STU:3NK

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price
€0.83
GF Value